These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
954 related articles for article (PubMed ID: 25368253)
21. PAI-1 expression and its regulation by promoter 4G/5G polymorphism in clear cell renal cell carcinoma. Choi JW; Lee JH; Park HS; Kim YS J Clin Pathol; 2011 Oct; 64(10):893-7. PubMed ID: 21725041 [TBL] [Abstract][Full Text] [Related]
22. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome. Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922 [TBL] [Abstract][Full Text] [Related]
23. NDRG2 is involved in the oncogenic properties of renal cell carcinoma and its loss is a novel independent poor prognostic factor after nephrectomy. Liang ZL; Kang K; Yoon S; Huang SM; Lim JS; Kim JM; Lim JS; Lee HJ Ann Surg Oncol; 2012 Aug; 19(8):2763-72. PubMed ID: 22246425 [TBL] [Abstract][Full Text] [Related]
24. Proteomic identification of angiomotin by ProteomeLab PF-2D and correlation with clinical outcome in human clear cell renal cell carcinoma. Yang J; Liu P; Tian M; Li Y; Chen W; Li X Int J Oncol; 2013 Jun; 42(6):2078-86. PubMed ID: 23588948 [TBL] [Abstract][Full Text] [Related]
25. Expression and cytoplasmic localization of SAM68 is a significant and independent prognostic marker for renal cell carcinoma. Zhang Z; Li J; Zheng H; Yu C; Chen J; Liu Z; Li M; Zeng M; Zhou F; Song L Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2685-93. PubMed ID: 19755649 [TBL] [Abstract][Full Text] [Related]
26. LIM and SH3 domain protein 1 (LASP-1) overexpression was associated with aggressive phenotype and poor prognosis in clear cell renal cell cancer. Yang F; Zhou X; Du S; Zhao Y; Ren W; Deng Q; Wang F; Yuan J PLoS One; 2014; 9(6):e100557. PubMed ID: 24955835 [TBL] [Abstract][Full Text] [Related]
27. High-level S100A6 promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma. Lyu X; Li H; Ma X; Li X; Gao Y; Ni D; Shen D; Gu L; Wang B; Zhang Y; Zhang X Cell Biochem Biophys; 2015 Jan; 71(1):279-90. PubMed ID: 25120023 [TBL] [Abstract][Full Text] [Related]
28. Down-regulation of miR-497 is associated with poor prognosis in renal cancer. Zhao X; Zhao Z; Xu W; Hou J; Du X Int J Clin Exp Pathol; 2015; 8(1):758-64. PubMed ID: 25755771 [TBL] [Abstract][Full Text] [Related]
29. High TXNDC5 expression predicts poor prognosis in renal cell carcinoma. Mo R; Peng J; Xiao J; Ma J; Li W; Wang J; Ruan Y; Ma S; Hong Y; Wang C; Gao K; Fan J Tumour Biol; 2016 Jul; 37(7):9797-806. PubMed ID: 26810069 [TBL] [Abstract][Full Text] [Related]
30. ΑB-crystallin in clear cell renal cell carcinoma: tumor progression and prognostic significance. Ho PY; Chueh SC; Chiou SH; Wang SM; Lin WC; Lee IL; Yang HY; Peng HC; Lai MK Urol Oncol; 2013 Oct; 31(7):1367-77. PubMed ID: 22417627 [TBL] [Abstract][Full Text] [Related]
31. SATB1 is Down-regulated in Clear Cell Renal Cell Carcinoma and Correlates with miR-21-5p Overexpression and Poor Prognosis. Kowalczyk AE; Krazinski BE; Godlewski J; Grzegrzolka J; Kiewisz J; Kwiatkowski P; Sliwinska-Jewsiewicka A; Dziegiel P; Kmiec Z Cancer Genomics Proteomics; 2016; 13(3):209-17. PubMed ID: 27107063 [TBL] [Abstract][Full Text] [Related]
32. MicroRNA-217, down-regulated in clear cell renal cell carcinoma and associated with lower survival, suppresses cell proliferation and migration. Li H; Zhao J; Zhang JW; Huang QY; Huang JZ; Chi LS; Tang HJ; Liu GQ; Zhu DJ; Ma WM Neoplasma; 2013; 60(5):511-5. PubMed ID: 23790169 [TBL] [Abstract][Full Text] [Related]
33. Down-regulation of human leukocyte antigen class I (HLA-I) is associated with poor prognosis in patients with clear cell renal cell carcinoma. Yuan J; Liu S; Yu Q; Lin Y; Bi Y; Wang Y; An R Acta Histochem; 2013 Jun; 115(5):470-4. PubMed ID: 23245688 [TBL] [Abstract][Full Text] [Related]
34. [Expression and role of vascular endothelial growth inhibitor in sporadic clear cell renal cell carcinoma]. Wu LY; Cheng H; Deng XH; Shan H; Wang W; Yang Y; Zhang XD; Zhang N Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(10):741-5. PubMed ID: 23755810 [TBL] [Abstract][Full Text] [Related]
35. Expression of Opa interacting protein 5 (OIP5) is associated with tumor stage and prognosis of clear cell renal cell carcinoma. Gong M; Xu Y; Dong W; Guo G; Ni W; Wang Y; Wang Y; An R Acta Histochem; 2013 Oct; 115(8):810-5. PubMed ID: 23664661 [TBL] [Abstract][Full Text] [Related]
36. Vascular endothelial growth inhibitor 174 is a negative regulator of aggressiveness and microvascular density in human clear cell renal cell carcinoma. Wu L; Li X; Ye L; Shayiremu D; Deng X; Zhang X; Jiang W; Yang Y; Gong K; Zhang N Anticancer Res; 2014 Feb; 34(2):715-22. PubMed ID: 24511004 [TBL] [Abstract][Full Text] [Related]
37. D9S168 microsatellite alteration predicts a poor prognosis in patients with clear cell renal cell carcinoma and correlates with the down-regulation of protein tyrosine phosphatase receptor delta. Li X; Tan X; Yu Y; Chen H; Chang W; Hou J; Xu D; Ma L; Cao G Cancer; 2011 Sep; 117(18):4201-11. PubMed ID: 21387281 [TBL] [Abstract][Full Text] [Related]
38. Hypoxia-induced overexpression of stanniocalcin-1 is associated with the metastasis of early stage clear cell renal cell carcinoma. Ma X; Gu L; Li H; Gao Y; Li X; Shen D; Gong H; Li S; Niu S; Zhang Y; Fan Y; Huang Q; Lyu X; Zhang X J Transl Med; 2015 Feb; 13():56. PubMed ID: 25740019 [TBL] [Abstract][Full Text] [Related]
39. Decreased ARID1A expression correlates with poor prognosis of clear cell renal cell carcinoma. Park JH; Lee C; Suh JH; Chae JY; Kim HW; Moon KC Hum Pathol; 2015 Mar; 46(3):454-60. PubMed ID: 25628030 [TBL] [Abstract][Full Text] [Related]
40. CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases. Wuttig D; Zastrow S; Füssel S; Toma MI; Meinhardt M; Kalman K; Junker K; Sanjmyatav J; Boll K; Hackermüller J; Rolle A; Grimm MO; Wirth MP Int J Cancer; 2012 Sep; 131(5):E693-704. PubMed ID: 22213152 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]